Key Highlights
● Zevra shares slid on Friday.
● A key EMA committee issued a negative opinion.
● The opinion covers its drug arimoclomol.
● Risk assets had a tough day overall.
Zevra Therapeutics (NASDAQ:ZVRA), a Nasdaq-listed company focused on treatments for rare diseases, fell sharply on Friday, November 13, 2026. The trigger was a negative opinion on arimoclomol from the Committee for Medicinal Products for Human Use, known as the CHMP, the European Medicines Agency's main committee for evaluating medicines.
But the market's reaction made clear how much weight investors had placed on a positive outcome.
How the European process works
As general context, a company seeking to sell a medicine across the European Union typically applies to the EMA through a centralized procedure. The CHMP reviews the application and issues an opinion, either positive or negative. The European Commission then makes the final legally binding decision, and it usually follows the committee's recommendation.
That is why a CHMP opinion is treated as a major milestone. A positive opinion often signals that approval is likely within a few months, while a negative one generally means the product will not be authorized in the EU on the current application. Companies can, in some cases, request a re-examination of a negative opinion, though the outcome of any such process is uncertain and timelines vary.
Why the stock reacted so strongly
For smaller drug developers, a single regulatory decision can carry outsized importance. As general context, rare-disease companies often rely on a limited number of products, and a major market such as Europe can represent a meaningful part of a drug's long-term Revenue potential. When a key path to that market narrows, investors quickly reprice their expectations.
Zevra's move came on a day when health care stocks were split between regulatory wins and setbacks. Tandem Diabetes Care (NASDAQ:TNDM) jumped after the US Food and Drug Administration cleared a tubeless option for its Tandem Mobi insulin pump, and Novo Nordisk (NYSE:NVO) announced EU approval of FREHEMGO for haemophilia A, according to market data. On the downside, Candel Therapeutics (NASDAQ:CADL) tumbled after pushing a planned approval filing for a prostate cancer treatment to mid-2027.
A tough day for risk assets
The broader market offered little support. The Nasdaq Composite fell 229.82 points to 25,136.27, and the Russell 2000, home to many smaller biotechs, dipped 8.57 points to 2,790.49. The S&P 500 slipped 30.73 points to 7,561.67 amid a chip-led selloff.
Rates were also a headwind. The October producer price index showed wholesale prices rising at their fastest annual pace since November 2022, and traders see a December Fed rate hike as near-certain, according to market data. The 10-year Treasury Yield climbed to its highest since October. As general context, higher rates tend to weigh on companies whose value depends on profits expected far in the future, a description that fits much of the biotech sector.
Elsewhere in the sector, Vir Biotechnology (NASDAQ:VIR) sank after pricing a share offering below its prior close, while Prime Medicine (NASDAQ:PRME) rose after closing a share sale that extended its cash runway through 2027. The contrast underlined how sensitive biotech investors are to both regulatory and funding news.
Zevra Therapeutics: the next catalysts
Investors will look for any statement from Zevra on how it plans to respond to the CHMP opinion, including whether it pursues a re-examination, and on how the decision affects its broader strategy. The European Commission's eventual decision will also be watched. Across biotech, Fed minutes on Wednesday will shape the rate backdrop for the sector.






Please wait processing your request...